RCUS
Arcus Biosciences, Inc.
Key Financials
Operating Income
$-386000000
↓ 17.0%
Revenue
$247.0M
↓ 4.3%
Total Assets
$1.1B
↓ 1.0%
Shareholders' Equity
$631.0M
↑ 30.1%
Net Income
$-353000000
↓ 24.7%
EPS (Diluted)
$-3.29
↓ 4.8%
Cash & Equivalents
$222.0M
↑ 48.0%
Long-term Debt
$99.0M
↑ 106.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| CT ORDER | 9/28/2026 | View on SEC |
| 4 | 8/24/2026 | View on SEC |
| 144 | 8/21/2026 | View on SEC |
| SCHEDULE 13D/A | 8/7/2026 | View on SEC |
| 10-Q | 8/5/2026 | View on SEC |
| 8-K | 8/5/2026 | View on SEC |
| 4 | 7/13/2026 | View on SEC |
| 144 | 7/9/2026 | View on SEC |
| 144 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RCUS |
| Company Name | Arcus Biosciences, Inc. |
| CIK | 1724521 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (510) 694-6200 |